- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
2020 was a year to remember, for so many reasons, but there is one reason that might not be obvious: it was the year of the IPO. The crazy corona crisis year didn’t just bring us social distancing and mass mask mandates, it also brought us a huge number of IPOs, with well over 200 companies entering the public realm – that’s 34% more than 2019, and the most since 2014.And, it was the year of unicorn, too. Unicorns, or billion-dollar start-ups, were more common than usual in the IPO ranks. The ag...
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, will be participating in a fireside chat at the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2, 2020 at 10:55 am EST.
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, and additional management will participate in the following upcoming virtual investor conferences:
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the presentation of first-time preclinical data for SQZ Antigen Presenting Cells (APCs) in combination with immune-oncology compounds in a poster at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) virtual poster sessions. A trial-in-progress poster for SQZ-PBMC-HPV-101 and additional posters of preclinical data from two proprietary cel...
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies (NYSE: SQZ) (“SQZ”) on the New York Stock Exchange (NYSE) as of October 30, 2020. This announcement marks Global Health Sciences (GHS) Fund’s third portfolio company to successfully go public after Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) in April 2018 and Keros Therapeutics, Inc. (NASDAQ: KROS) in Ap...
Cell therapy and technologies company SQZ Biotechnologies began trading on the NYSE today. Armon Sharei, CEO of SQZ Biotechnologies, joins Yahoo Finance's Zack Guzman and Anjalee Khemlani to discuss.
SQZ Biotechnologies Company (NYSE: SQZ) ("SQZ") today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by SQZ. In addition, SQZ has granted the underwriters a 30-day option to purchase up to an additional 661,764 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any....